Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Epitope analyses of AT AA
2019-09-18
Epitope analyses of AT1-AA and ET-AA indicate that the conotoxin of both autoantibodies are located at the second extracelluar loop of both receptors. The specific epitopes for both autoantibodies are similar to what was reported previously in a cohort of patients from Brazil [6] and for AT1-AA also
-
In this study we also
2019-09-18
In this study, we also conducted an analysis comparing the expression profiling of Hh genes among the sarcomas investigated. In these tumors, the IHH gene showed a higher expression level than PTCH1 gene in RMS and SS samples (pKC7F2 and in human RMS cell lines as well as mouse NIH-3T3 fibroblasts.
-
SP 600125 The H E staining and Nissl staining results
2019-09-18
The H&E staining and Nissl staining results showed that damage to the pyramidal neurons in the CA1 and CA3 regions of the hippocampus were observed in the 50 mg/kg/day DBP group, accompanied by an absence of Nissl bodies, suggesting that DBP exposure can lead to pathological changes in the neurons o
-
br Methods br Discussion In a recent
2019-09-17
Methods Discussion In a recent survey among 2625 high risk patients on atorvastatin, 10.5% of patients achieved an LDL-target of and ache inhibitors level for improvement of acceptance and adherence to effective lipid lowering therapy are warranted to maximize the benefits of standard treatme
-
br Results br Discussion The advent of TKI treatment
2019-09-17
Results Discussion The advent of TKI treatment has greatly improved CML therapy. Because CML LSCs are less sensitive to TKIs, CML is usually controlled rather than cured, highlighting an unmet clinical need. Developed from our previous finding that CML LSCs are more dependent on Tcf1 and Lef1
-
This study showed that ER
2019-09-17
This study showed that ER-redox disturbance-associated ER stress is linked to cytoplasmic chaperone signaling, including HSP90 stability and its client protein, eNOS. The highly increased PERK and IRE-1α lead to dissociation with the chaperone protein, thereby decreasing HSP90 stability (Fig. 5B). S
-
Recent results from our group found that SPMs not only
2019-09-17
Recent results from our group found that SPMs, not only play a part in terminating inflammation, but also have a physiological role in conjunctival goblet potassium channel to maintain ocular surface health in the absence of disease. Amongst the SPMs that are effective in the conjunctiva are resolv
-
The molecular mechanism by which CRM regulates IEC apoptosis
2019-09-17
The molecular mechanism by which CRM1 regulates IEC apoptosis in CD remains to be explored. As an inhibitor of cyclin E-Cdk2, p27kip1 plays a pivotal role in controlling cell proliferation, S phase entry, and G1 phase exit during development and tumorigenesis [38]. As previously reported, p27kip1 is
-
LY2409881 Secondary and primary studies have considered
2019-09-17
Secondary and primary studies have considered the decision to select the provider and to select components after the component origin is chosen. Examples of secondary and primary studies outside our scope, but still related to decision-making are listed in Tables 1 and 2. The secondary and primary s
-
L 012 sodium salt mass br Introduction Vein graft implantati
2019-09-16
Introduction Vein graft implantation into the arterial environment for surgical bypass is the gold standard to treat severe cardiovascular occlusive disease. After placement of a vein into the higher pressure, flow, and oxygen tension of the arterial circulation, the vein adapts to the arterial e
-
br Introduction Esophageal squamous cell carcinoma ESCC is o
2019-09-16
Introduction Esophageal squamous cell carcinoma (ESCC) is one of the most common types of cancer in East Asia and is a leading cause of cancer-related death worldwide.1, 2 Surgery is widely used for treatment in localized disease, where it can provide definitive management and potential cure. Tre
-
br Cysteine proteases as molecular targets for
2019-09-16
Cysteine proteases as molecular targets for trypanosomatid diseases Approaches relying on a molecular target, such as SBDD and target-based screening, have supported outstanding scientific developments in current pharmaceutical R&D. By integrating experimental and computational methods, these str
-
At baseline mutant allele frequency of
2019-09-12
At baseline, mutant allele frequency of EGFR in tissue and plasma samples did not correlated with anti-tumor response (Supplementary Fig. 1). Among 35 patients who were positive for cell-free DNA (cfDNA) at baseline, changes of cfDNA during treatment were analyzed. Negative conversion (NC) of cfDNA
-
DC_AC50 clinical Although our knowledge of the biochemical a
2019-09-12
Although our knowledge of the biochemical and biological functions of E3 ubiquitin ligases has increased in B-cell malignancies, a deeper characterization of cell-context dependent substrate regulation and biological relevance is needed. The recent approval of a general proteasome inhibitor, VELCADE
-
br Results br Discussion In
2019-09-12
Results Discussion In this paper we present insights into the observed specificities of inhibitors targeting the ubiquitin-activating and related E1 HMP Linker kinase via crystal structures of the specific NEDD8-E1 inhibitor MLN4924, the dual NEDD8/Ub E1 inhibitor ABPA3, and the selective Ub-
15740 records 948/1050 page Previous Next First page 上5页 946947948949950 下5页 Last page